A. Rost

3.2k total citations · 1 hit paper
12 papers, 1.2k citations indexed

About

A. Rost is a scholar working on Oncology, Pathology and Forensic Medicine and Pulmonary and Respiratory Medicine. According to data from OpenAlex, A. Rost has authored 12 papers receiving a total of 1.2k indexed citations (citations by other indexed papers that have themselves been cited), including 9 papers in Oncology, 5 papers in Pathology and Forensic Medicine and 3 papers in Pulmonary and Respiratory Medicine. Recurrent topics in A. Rost's work include Colorectal Cancer Treatments and Studies (5 papers), Cancer Treatment and Pharmacology (4 papers) and Lymphoma Diagnosis and Treatment (3 papers). A. Rost is often cited by papers focused on Colorectal Cancer Treatments and Studies (5 papers), Cancer Treatment and Pharmacology (4 papers) and Lymphoma Diagnosis and Treatment (3 papers). A. Rost collaborates with scholars based in Germany and Switzerland. A. Rost's co-authors include Mathias Rummel, Paris S. Mitrou, Andreas Schalhorn, D. Quietzsch, H Schönekäs, Caroline Haag, Axel Holstege, Horst Neuhaus, D. Uthgenannt and Ursula Vehling‐Kaiser and has published in prestigious journals such as Journal of Clinical Oncology, Blood and Annals of Oncology.

In The Last Decade

A. Rost

12 papers receiving 1.1k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Randomized Phase III Trial of Gemcitabine Plus Cisplatin Compared With Gemcitabine Alone in Advanced Pancreatic Cancer

2006 535 citations Volker Heinemann, D. Quietzsch et al. Journal of Clinical Oncology profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
A. Rost Germany	7	869	383	363	273	240	12	1.2k
Olga Balagué Spain	22	686 0.8×	827 2.2×	202 0.6×	274 1.0×	285 1.2×	51	1.6k
Dianna Shipley United States	20	724 0.8×	288 0.8×	453 1.2×	61 0.2×	148 0.6×	68	1.1k
M. Luisa Paccagnella United States	13	857 1.0×	283 0.7×	275 0.8×	143 0.5×	210 0.9×	22	1.7k
S. Al-Batran Germany	15	729 0.8×	411 1.1×	680 1.9×	262 1.0×	108 0.5×	40	1.5k
Xiaopei Zhu United States	15	354 0.4×	172 0.4×	484 1.3×	68 0.2×	107 0.4×	22	1.1k
Carmelo Bengala Italy	15	952 1.1×	221 0.6×	332 0.9×	68 0.2×	238 1.0×	40	1.3k
Junning Cao China	16	553 0.6×	381 1.0×	213 0.6×	109 0.4×	56 0.2×	90	907
José María Sayagués Spain	23	292 0.3×	249 0.7×	131 0.4×	231 0.8×	216 0.9×	66	1.3k
Stefanie Srock Germany	12	787 0.9×	506 1.3×	302 0.8×	246 0.9×	154 0.6×	21	1.1k
Myung Hee Chang South Korea	17	385 0.4×	205 0.5×	246 0.7×	73 0.3×	81 0.3×	50	718

Countries citing papers authored by A. Rost

Since Specialization

Citations

This map shows the geographic impact of A. Rost's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by A. Rost with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites A. Rost more than expected).

Fields of papers citing papers by A. Rost

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by A. Rost. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by A. Rost. The network helps show where A. Rost may publish in the future.

Co-authorship network of co-authors of A. Rost

This figure shows the co-authorship network connecting the top 25 collaborators of A. Rost. A scholar is included among the top collaborators of A. Rost based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with A. Rost. A. Rost is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

12 of 12 papers shown

Huober, Jens, W. Fett, Arnd Nusch, et al.. (2010). A multicentric observational trial of pegylated liposomal doxorubicin for metastatic breast cancer. BMC Cancer. 10(1). 2–2. 40 indexed citations

Heinemann, Volker, D. Quietzsch, Frank Gieseler, et al.. (2006). Randomized Phase III Trial of Gemcitabine Plus Cisplatin Compared With Gemcitabine Alone in Advanced Pancreatic Cancer. Journal of Clinical Oncology. 24(24). 3946–3952. 535 indexed citations breakdown →

Rummel, Mathias, S. Al-Batran, Manfred Welslau, et al.. (2005). Bendamustine Plus Rituximab Is Effective and Has a Favorable Toxicity Profile in the Treatment of Mantle Cell and Low-Grade Non-Hodgkin's Lymphoma. Journal of Clinical Oncology. 23(15). 3383–3389. 332 indexed citations

Rummel, Mathias, Stephan Stilgenbauer, H. Gamm, et al.. (2005). Fludarabine Versus Fludarabine Plus Epirubicin in the Treatment of Chronic Lymphocytic Leukemia - Final Results of a German Randomized Phase-III Study.. Blood. 106(11). 2123–2123. 5 indexed citations

Al‐Batran, Salah‐Eddin, Akin Atmaca, Susanna Hegewisch‐Becker, et al.. (2004). Phase II Trial of Biweekly Infusional Fluorouracil, Folinic Acid, and Oxaliplatin in Patients With Advanced Gastric Cancer. Journal of Clinical Oncology. 22(4). 658–663. 152 indexed citations

Weidmann, Eckhart, et al.. (2002). Bendamustine is effective in relapsed or refractory aggressive non-Hodgkin’s lymphoma. Annals of Oncology. 13(8). 1285–1289. 72 indexed citations

Hartung, G., Ralf‐Dieter Hofheinz, A. Wein, et al.. (2001). Phase II Study of a Weekly 24-Hour Infusion with 5-Fluorouracil and Simultaneous Sodium – Folinic Acid in the First-Line Treatment of Metastatic Colorectal Cancer. Oncology Research and Treatment. 24(5). 457–462. 12 indexed citations

Hartung, G., Ralf‐Dieter Hofheinz, Dieter Buchheidt, et al.. (2000). Combination of Bolus 5-Fluorouracil, Folinic Acid and Mitomycin C in Advanced Gastric Cancer: Results of a Phase II Trial. Oncology Research and Treatment. 23(5). 444–447. 9 indexed citations

Hofheinz, Ralf‐Dieter, G. Hartung, A. Wein, et al.. (1999). Phase-II-study of a 24-h infusion with 5-fluorouracil (5-FU) and simultaneous sodium-folinic acid in the first-line-treatment of advanced colorectal cancer: interim analysis. European Journal of Cancer. 35. S81–S81. 2 indexed citations

10.

Gleissner, Beate, A. Hellmann, Lutz Edler, et al.. (1998). Phase I/II Study of Paclitaxel and 5-Fluorouracil as Second-Line Therapy in Patients with Metastatic Breast Cancer. Oncology Research and Treatment. 21(4). 305–308. 1 indexed citations

11.

Rost, A., et al.. (1967). [Further animal experiments on the anti-inflammatory action of hostacain].. PubMed. 22(9). 1106–13. 2 indexed citations

12.

Rost, A., et al.. (1967). [Animal experiments for the study of the antiphlogistic action of hostacain and oxyprocaine forte].. PubMed. 22(2). 367–71. 2 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact